About Molecule Signal

Molecule Signal covers drug development the way filings read, not the way press releases sound: FDA and EMA actions, clinical trial changes, drug recalls and shortages, and the deals and financings disclosed in SEC filings. Short briefs, timestamps, and a source list on every story.

Methodology

We monitor official sources directly: FDA feeds and databases, the openFDA APIs, ClinicalTrials.gov, EMA announcements, and SEC EDGAR filings. Trade publications are never copied or paraphrased; when we link out to other outlets' reporting, the credit and the click go to them. Briefs are drafted with software assistance from official-source data; every published item is reviewed and fact-checked by the editor before publication.

Sourcing policy

Every material claim in a brief traces to a linked primary source. Facts known only from a company's own statement or filing are attributed to the company ("the company said," "according to the filing"), not stated as independently established. Preliminary results and sponsor claims of efficacy are labeled for what they are.

Corrections

When we get something material wrong, the fix is visible: a dated correction note appears on the story, and the story is never silently rewritten. To report an error, email aristotlemalichetty@gmail.com.

Who runs this

Molecule Signal is edited and fact-checked by Aristotle Malichetty.

Disclaimers

Nothing on this site is medical advice; do not rely on it to make decisions about medical care. Nothing on this site is investment advice.